Cancer Research UK
Irish Cancer Society
Macmillan Cancer Support
NHS Evidence
Epirubicin – Substance Summary
PubChem
MedlinePlus
– See more at: http://www.cancerindex.org/Epirubicin#sthash.BBioCC6K.dpuf
PHASE 1 JAPAN SOLID TUMOURS
DNA/RNA Synthesis Inhibitor
WITH Nano Carrier Co.,Ltdhttp://pdf.irpocket.com/C4571/qnwX/eFou/vG1J.pdf
KOWA COMPANY LTD
CAS FREE FORM. 56420-45-2
Smiles
- O=C2c1c(O)c5c(c(O)c1C(=O)c3cccc(OC)c23)C[C@@](O)(C(=O)CO)C[C@@H]5O[C@@H]4O[C@H]([C@H](O)[C@@H](N)C4)C
- NMR
- http://file.selleckchem.com/downloads/nmr/S122302-Epirubicin-Hydrochloride-NMR-Selleck.pdf
- http://www.medkoo.com/Product-Data/Epirubicin/Epirubicin-QC-TZC20130604web.pdf
-
Epirubicin CAS No.: 56420-45-2 Synonyms: - 4′-Epi-DX;
- Epirubicina;
- WP 697;
- Pidorubicin;
- 4′-epiadriamycin;
- Adriblastin;
- epi-dx;
- Epiadriamycin;
- farmorubicin;
- imi28;
- Farmarubicin;
Formula: C27H29NO11 Exact Mass: 543.17400
NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin.
Epirubicin is widely used to treat various human tumors. However, it is difficult to achieve a sufficient antitumor effect because of dosage limitation to prevent cardiotoxicity. We hypothesized that epirubicin-incorporating micelle would reduce cardiotoxicity and improve the antitumor effect. NC-6300 comprises epirubicin covalently bound to PEG polyaspartate block copolymer through an acid-labile hydrazone bond. The conjugate forms a micellar structure of 40-80 nm in diameter in an aqueous milieu. NC-6300 (10, 15 mg/kg) and epirubicin (10 mg/kg) were given i.v. three times to mice bearing s.c. or liver xenograft of human hepatocellular carcinoma Hep3B cells. Cardiotoxicity was evaluated by echocardiography in C57BL/6 mice that were given NC-6300 (10 mg/kg) or epirubicin (10 mg/kg) in nine doses over 12 weeks. NC-6300 showed a significantly potent antitumor effect against Hep3B s.c. tumors compared with epirubicin. Moreover, NC-6300 also produced a significantly longer survival rate than epirubicin against the liver orthotopic tumor of Hep3B. With respect to cardiotoxicity, epirubicin-treated mice showed significant deteriorations in fractional shortening and ejection fraction. In contrast, cardiac functions of NC-6300 treated mice were no less well maintained than in control mice. This study warrants a clinical evaluation of NC-6300 in patients with hepatocellular carcinoma or other cancers.
K-912(NC-6300)の概要 K-912(NC-6300)は、世界的に幅広く使用されているアントラサイクリン系の抗が ん剤の一つであるエピルビシンを内包したミセル化ナノ粒子製剤で、その特性により、 エピルビシンの有する心毒性の軽減が期待できます。さらに、pH 応答性システムを採 用することで、腫瘍細胞内でのエピルビシンの放出量を高め、既存のエピルビシンに比 べより強力な抗腫瘍効果が期待できます。
Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is marketed by Pfizer under the trade name Ellence in the US andPharmorubicin or Epirubicin Ebewe elsewhere.
Similarly to other anthracyclines, epirubicin acts by intercalating DNA strands. Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage by topoisomerase II, resulting in mechanisms that lead to cell death. Binding to cell membranes and plasma proteins may be involved in the compound’s cytotoxic effects. Epirubicin also generates free radicalsthat cause cell and DNA damage.
Epirubicin is favoured over doxorubicin, the most popular anthracycline, in some chemotherapy regimens as it appears to cause fewer side-effects. Epirubicin has a different spatial orientation of the hydroxyl group at the 4′ carbon of the sugar – it has the opposite chirality – which may account for its faster elimination and reduced toxicity. Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer and lymphomas.
Development history
The first trial of epirubicin in humans was published in 1980.[1] Upjohn applied for approval by the U.S. Food and Drug Administration(FDA) in node-positive breast cancer in 1984, but was turned down because of lack of data.[2] It appears to have been licensed for use in Europe from around this time however.[3] In 1999 Pharmacia (who had by then merged with Upjohn) received FDA approval for the use of epirubicin as a component of adjuvant therapy in node-positive patients.
Patent protection for epirubicin expired in August 2007.
References
- Bonfante, V; Bonadonna, G; Villani, F; Martini, A (1980). “Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia”. Recent results in cancer research 74: 192–9. PMID 6934564. PM6934564.
- “On Target”.
- According to the proprietary database iddb.com
External links
- http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Epirubicin.htm
- http://www.pfizerpro.com/page_not_found?rid=/wyeth_html/home/minisites/oncology/ellence/pi/description.html
1H NMR PREDICT
13C NMR PREDICT
COSY
1H NMR
![]() |
|
![]() |
|
Systematic (IUPAC) name | |
---|---|
(8R,10S)-10-((2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione | |
Clinical data | |
Trade names | Ellence |
AHFS/Drugs.com | monograph |
MedlinePlus | a603003 |
Intravenous | |
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | 77% |
Metabolism | Hepatic glucuronidationand oxidation |
Excretion | Biliary and renal |
Identifiers | |
56420-45-2 ![]() |
|
L01DB03 | |
PubChem | CID 41867 |
DrugBank | DB00445 ![]() |
ChemSpider | 38201 ![]() |
UNII | 3Z8479ZZ5X ![]() |
KEGG | D07901 ![]() |
ChEBI | CHEBI:47898 ![]() |
ChEMBL | CHEMBL417 ![]() |
Chemical data | |
Formula | C27H29NO11 |
543.519 g/mol |
KOWA COMPANY LTD




P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
Filed under: cancer, Japan marketing, Japan pipeline, PHASE1, Uncategorized Tagged: epirubicin, Epirubicin nano, JAPAN, K 912, K-912 NC-6300, kowa, NC 6300, PHASE 1
